Efficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis.

NCT ID: NCT03729258

Last Updated: 2023-01-05

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-05-15
• Study Completion Date: 2023-12-01

Brief Summary

The aim of this study is to compare the efficacy and safety of cefpodoxime 200 mg immediate (b.i.d) and cefpodoxime 400 mg modified release (q.d) tablet formulations in the treatment of acute bacterial rhinosinusitis.

Conditions

Sinusitis; Sinusitis, Acute; Rhinosinusitis; Rhinosinusitis Acute; Sinus Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Cefpodoxime 200 (b.i.d)

Group Type: EXPERIMENTAL

Infex 200 IR

Intervention Type: DRUG

Infex (cefpodoxime) 200mg twice a day (BID) for 10 days

Cefpodoxime 400 (q.d)

Group Type: ACTIVE_COMPARATOR

Infex 400 MR

Intervention Type: DRUG

Infex (cefpodoxime) 400mg once a day (QD) for 10 days

Interventions

Infex 400 MR

Infex (cefpodoxime) 400mg once a day (QD) for 10 days

Intervention Type: DRUG

Infex 200 IR

Infex (cefpodoxime) 200mg twice a day (BID) for 10 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. 18 years and older patients who have acute bacterial rhinosinusitis sign and symptoms (i, ii, iii) according to IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults: i. Onset with persistent symptoms or signs* compatible with acute rhinosinusitis, lasting for ≥ 10 days without any evidence of clinical improvement, ii. Onset with severe symptoms or signs of high fever > 39 and purulent nasal discharge or facial pain lasting for at least 3-4 consecutive days at the beginning of illness, iii. Onset with worsening symptoms or signs characterized by the new onset of fever, headache, or increase in nasal discharge that lasted 5-6 days and were initially improving.

(*Major symptoms: Purulent anterior nasal discharge, Purulent or discolored posterior nasal discharge, Nasal congestion or obstruction, Facial congestion or fullness, Facial pain or pressure, d Hyposmia or anosmia. *Minor symptoms: Headache, Ear pain, pressure, or fullness, Halitosis, Dental pain, Cough, Fatigue)

2. Patients who are able to give culture sample from middle meatus (microorganisms to be teste: Streptococcus pneumoniae, Haemophilus influenzae [including beta-lactamase producing strains], Streptococcus pyogenes and Moraxella catarrhalis [including beta-lactamase producing strains]).

3. Patients who are able to use oral drugs,

4. If patient is a women of childbearing age; female patients who applies appropriate birth control,

5. Patients who have ability to communicate with investigators,

6. Patients who commits to adhere to the study protocol,

7. Patients who sign informed consent form.

Exclusion Criteria

1. Patients who have hypersensitivity to beta-lactam antibiotics, penicillin and cefpodoxime,

2. Patients who hypersensitivity to peanut and soy,

3. Patients who have kidney or liver deficiency,

4. Patients who have history of more than 2 bacterial sinusitis episode within last 12 months,

5. Patients who have chronic sinusitis,

6. Patients who have history of head and neck surgery and/or severe sinusitis complication (brain abscess or venous thrombosis),

7. Patients who are hospitalized within 4 weeks prior to the start of study,

8. Patients who have immunodeficiency (i.e; HIV, corticosteroid use, immunosuppressive use),

9. Patients who used antibiotics within 30 days prior to the start of study,

10. Patients who need to use of antibiotics other than investigational drugs for concomitant disease,

11. Patients who used aluminium and magnesium containing anti-acids, probenecid and iron containing drugs within 2 weeks prior to the start of study,

12. Pregnant and lactating female patients.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Neutec Ar-Ge San ve Tic A.Ş

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Bakırköy Dr. Sadi Konuk Training and Research Hospital

Istanbul, , Turkey (Türkiye)

Site Status: RECRUITING

Countries

Turkey (Türkiye)

Central Contacts

Neutec RDC

Role: CONTACT

iremkaraman@neutecrdc.com

00905051747902

Facility Contacts

İbrahim Sayın, Assoc Prof Dr

Role: primary

Role: backup

dribrahimsayin@yahoo.com

Other Identifiers

NEU-04.15

Identifier Type: -

Identifier Source: org_study_id